Antivascular endothelial growth factor (VEGF) agents have provided historic therapeutic breakthroughs in the treatment of retinal disease. New anti-VEGF agents are emerging for the treatment of retinal vascular diseases. Both systemic and ocular adverse effect need to be understood in managing patients. This review aims to highlight the adverse effects seen with routine use of bevacizumab, ranibizumab and aflibercept, as well as with new medications such as brolucizumab and abicipar.

中文翻译：

---

抗血管内皮生长因子药物的药物相关不良反应。

抗血管内皮生长因子（VEGF）药物为视网膜疾病的治疗提供了历史性的治疗突破。用于治疗视网膜血管疾病的新型抗 VEGF 药物正在出现。在管理患者时需要了解全身和眼部的不良反应。本综述旨在强调常规使用贝伐单抗、雷珠单抗和阿柏西普以及新药（如 brolucizumab 和 abicipar）所观察到的不良反应。